Dermatology
Audio Summaries

The UCL-Lancet Commission on Migration and Health: review of the state of progress

The authors review the progress made since the UCL-Lancet Commission on Migration and Health's 2018 publication, highlighting the urgent need for improved health care access for refugees and migrants amid rising global migration trends and the impacts of the COVID-19 pandemic. They emphasize the importance of incorporating health considerations into migration policies, establishing monitoring systems, and addressing the health consequences of climate change. Ultimately, the authors call for strong leadership and accountability to enhance the health outcomes and rights of people on the move.

Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data

The authors aimed to investigate the impact of the HPV vaccination program on cervical cancer mortality trends in England from 2001 to 2024, particularly among young women. Their analysis revealed a significant reduction in cervical cancer deaths, with a 100% mortality reduction in women aged 20-24 who were vaccinated at ages 12-13, supporting the effectiveness of high vaccination coverage in achieving cervical cancer elimination goals.

Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial

The authors aimed to compare the efficacy and safety of benzylpenicillin versus anti-staphylococcal penicillins (flucloxacillin or cloxacillin) in treating penicillin-susceptible Staphylococcus aureus bacteraemia in adults. Although the study did not meet the prespecified non-inferiority criterion for mortality, benzylpenicillin demonstrated a high probability of non-inferiority and a significantly lower risk of acute kidney injury, suggesting it may be the preferred treatment option.

Management of Differentiated Thyroid Cancer

The authors aim to establish a comprehensive framework for the risk-adapted management of differentiated thyroid cancer, emphasizing the importance of dynamic risk stratification throughout the patient's clinical journey. They explore how clinicopathological staging and molecular risk characterization inform personalized management plans, particularly in the contexts of active surveillance for low-risk cases and treatment options for advanced disease. The paper illustrates therapeutic decision-making processes that balance risks, benefits, and patient preferences to enhance management strategies.

Cefazolin for Methicillin-Susceptible <em>Staphylococcus aureus</em> Bacteremia

The authors aimed to determine whether cefazolin is noninferior to antistaphylococcal penicillins (flucloxacillin or cloxacillin) in treating methicillin-susceptible *Staphylococcus aureus* bacteremia, particularly regarding 90-day mortality rates. The study found that cefazolin demonstrated noninferiority in mortality outcomes and was associated with a lower incidence of acute kidney injury compared to the penicillin group.

Patellar resurfacing in total knee replacement: 20-year clinical and economic results of a large multicentre, randomised controlled trial in the UK

This study aimed to evaluate the long-term clinical and economic outcomes of patellar resurfacing during total knee replacement (TKR) over a 20-year period. The findings indicated no significant difference in the primary outcome measure, the Oxford Knee Score, between resurfaced and non-resurfaced groups; however, the resurfaced group demonstrated significantly higher quality-adjusted life-years (QALYs) and a high probability of being cost-effective. Overall, the evidence suggests that patellar resurfacing may be the preferred approach in TKR despite the lack of significant differences in some clinical endpoints.

SPIRIT 2025 statement: updated guideline for protocols of randomised trials

The authors aimed to systematically update the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines to enhance the completeness and relevance of randomized trial protocols. Through a Delphi consensus process involving 317 participants, they introduced new items, revised existing ones, and integrated recommendations from other reporting guidelines, resulting in a comprehensive checklist of 34 minimum items for trial protocols. The updated SPIRIT 2025 statement is designed to improve transparency and completeness, benefiting various stakeholders in the research community.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma

The authors aimed to evaluate the efficacy of talquetamab in combination with daratumumab and pomalidomide (Tal-DP) compared to daratumumab plus pomalidomide and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma. The phase 3 trial demonstrated that both Tal-DP and talquetamab plus daratumumab (Tal-D) significantly improved progression-free survival and overall response rates compared to DPd, indicating a promising treatment option for this patient population.

Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema

The authors aimed to evaluate the efficacy and safety of lonvoguran ziclumeran (lonvo-z), an investigational CRISPR-based gene-editing treatment, in reducing the frequency of attacks in patients with hereditary angioedema due to C1 inhibitor deficiency. In a phase 3 trial, a single intravenous infusion of lonvo-z significantly decreased the monthly attack rate compared to placebo, with a relative reduction of 87%. While adverse events were reported in both groups, no serious complications occurred in the lonvo-z group, indicating a favorable safety profile.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

The SUCCESSOR-2 trial aimed to evaluate the efficacy and safety of mezigdomide in combination with carfilzomib and dexamethasone compared to carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma. Results showed that the mezigdomide combination significantly improved progression-free survival (18.0 months vs. 8.3 months) but was associated with higher rates of grade 3 or 4 adverse events. These findings suggest that mezigdomide-carfilzomib-dexamethasone is a promising treatment option for patients with limited therapeutic options due to prior exposure to anti-CD38 antibodies and lenalidomide.